Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$748 Mln
Revenue (TTM)
$213 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
--
EV/EBITDA
-8.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
333,934,016
CFO
$-1,486.18 Mln
EBITDA
$-1,911.10 Mln
Net Profit
$-1,914.31 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
| -69.1 | 30.9 | -40.1 | -73.4 | -34.9 | -40.0 | -14.6 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
| -8.9 | 27.2 | -66.5 | -58.9 | 67.6 | 212.8 | 10.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Iovance Biotherapeutics (IOVA)
|
2.3 | 748.0 | 212.7 | -375.4 | -145.6 | -48.7 | -- | 1.0 |
| 51.0 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.6 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 54.0 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.6 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 302.7 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.6 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 125.2 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 | |
| 284.4 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the... United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070 Read more
Interim CEO, President, General Counsel & Corporate Secretary
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim CEO, President, General Counsel & Corporate Secretary
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Headquarters
San Carlos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Iovance Biotherapeutics Inc (IOVA) stood at $ 1,089 Mln as on 31-Mar-25
The share price of Iovance Biotherapeutics Inc (IOVA) is $2.29 (NASDAQ) as of 13-Jun-2025 13:34 EDT. Iovance Biotherapeutics Inc (IOVA) has given a return of -34.9% in the last 3 years.
Iovance Biotherapeutics Inc (IOVA) has a market capitalisation of $ 748 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Iovance Biotherapeutics Inc (IOVA) is 0.97 times as on 12-Jun-2025, a 63% discount to its peers’ median range of 2.65 times.
Since, TTM earnings of Iovance Biotherapeutics Inc (IOVA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Iovance Biotherapeutics Inc (IOVA) and enter the required number of quantities and click on buy to purchase the shares of Iovance Biotherapeutics Inc (IOVA).
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070
The CEO & director of Dr. Frederick G. Vogt Esq., J.D., Ph.D.. is Iovance Biotherapeutics Inc (IOVA), and CFO & Sr. VP is Dr. Frederick G. Vogt Esq., J.D., Ph.D..
There is no promoter pledging in Iovance Biotherapeutics Inc (IOVA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Iovance Biotherapeutics Inc. (IOVA) | Ratios |
|---|---|
|
Return on equity(%)
|
-48.71
|
|
Operating margin(%)
|
-145.62
|
|
Net Margin(%)
|
-176.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Iovance Biotherapeutics Inc (IOVA) was $0 Mln.
$-0.02
(
